|
|
Volumn 420, Issue 6916, 2002, Pages 595-
|
|
Safety panel backs principle of gene-therapy trials
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
CANCER RISK;
COMBINED IMMUNODEFICIENCY;
GENE DELIVERY SYSTEM;
GENE THERAPY;
HUMAN;
INFORMED CONSENT;
NOTE;
PATIENT MONITORING;
PRIORITY JOURNAL;
SAFETY;
ARTICLE;
BIOMEDICAL AND BEHAVIORAL RESEARCH;
CHILD;
CLINICAL TRIAL;
FOOD AND DRUG ADMINISTRATION;
FRANCE;
GENETICS;
GENETICS AND REPRODUCTION;
HEALTH CARE ORGANIZATION;
LEGAL APPROACH;
LEGAL ASPECT;
LEUKEMIA;
MALE;
MONITORING;
PRACTICE GUIDELINE;
PROFESSIONAL STANDARD;
RECOMBINANT DNA ADVISORY COMMITTEE;
STANDARD;
UNITED STATES;
BIOMEDICAL AND BEHAVIORAL RESEARCH;
GENETICS AND REPRODUCTION;
LEGAL APPROACH;
RECOMBINANT DNA ADVISORY COMMITTEE;
CHILD;
CLINICAL TRIALS;
CLINICAL TRIALS DATA MONITORING COMMITTEES;
FRANCE;
GENE THERAPY;
HUMANS;
LEUKEMIA;
MALE;
MONITORING, PHYSIOLOGIC;
NATIONAL INSTITUTES OF HEALTH (U.S.);
PRACTICE GUIDELINES;
SEVERE COMBINED IMMUNODEFICIENCY;
UNITED STATES;
UNITED STATES FOOD AND DRUG ADMINISTRATION;
|
|
EID: 85047688768
PISSN: 00280836
EISSN: None
Source Type: Journal
DOI: 10.1038/420595b Document Type: Note |
|
Times cited : (13)
|
|
References (0)
|